Moving disease biology from the laboratory to the clinic

Seminars in Oncology

Volumn 29, Issue 6 SUPPL. 17, 2002, Pages 17-20

  Anderson, Kenneth C ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CYTOKINE; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; PROTEASOME INHIBITOR; SCLEROPROTEIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RESISTANCE; CELL ADHESION; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TARGETING; HUMAN; LABORATORY; MEDICAL RESEARCH; MULTIPLE MYELOMA; MYELOMA CELL; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; SIDE EFFECT; SIGNAL TRANSDUCTION; STROMA CELL;

EID: 0037249866     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34072     Document Type: Article

References (15)

1. Teoh G, Anderson C: Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 11:27-42, 1997
2. Chauhan D, Uchiyama H, Akbarali Y, et al: Multiple myeloma cell adhesiom-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87:1104-1112, 1996
3. Hideshima T, Chauhan D, Schlossman R, et al: The role of tumor necrosis factor in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20:4519-4527, 2001
4. 1: Differential effects on multiple myeloma versus normal B cells. Blood 87:1928-1938, 1996
5. Podar K, Tai YT, Davies FE, et al: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98:428-435, 2001
6. Ogata A, Chauhan D, Teoh G, et al: Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 159:2212-2221, 1997
7. Hideshima T, Chauhan D, Shima Y, et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96:2943-2950, 2000
8. Gupta D, Treon SP, Shima Y, et al: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 15:1950-1961, 2001
9. Lentzsch S, LeBlanc R, Podar K, et al: Thalidomide and its immunomodulatory analogs inhibit human multiple myeloma cell growth and angiogenesis in vivo. Leukemia (in press)
10. Davies FE, Raje N, Hideshima T, et al: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216, 2001
11. Treon SP, Mitsiades C, Mitsiades N, et al: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in B-cell malignancies. J Immunother 24:263-271, 2001
12. Richardson PG, Schlossman RL, Hideshima T: A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). Presented at the American Society of Hematology 43rd Annual Meeting, December 2001, Orlando, FL (abstr 3225)
13. Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91:3-21, 1998
14. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
15. Richardson P: Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Presented at the American Society of Hematology 43rd Annual Meeting, December 2001, Orlando, FL (abstr 3223)